VRTOG

Veterinary Radiation Therapy Oncology Group

Executive Committee (2012)

• Dr. Michelle Turek, Chair
• Dr. David Lurie, Assistant Chair
• Dr. Jeannie Poulson, Member At Large
• Dr. John Farrelly, Member At Large
• Dr. Mary K. Klein, Ex Officio; President, Recognized Specialty of Radiation Oncology

VRTOG Standard Operating Procedures

• VRTOG_SOP.pdf (Revised: 4/23/2004)

Business Meeting Minutes

• vrtog_00.pdf (12/2/2000)
• VRTOG_ACVR_2010.pdf (8/18/2010)
• VRTOG_VCS_2010.pdf (10/30/2010)

ACTIVITIES

Examining the Efficacy of Toceranib Phosphate (Palladia®) as a Primary and/or Adjuvant Agent in the Treatment of Feline Oral Squamous Cell Carcinoma – Feline SCC toceranib +/- RT.pdf (ACVR ID/Password required) This study is currently recruiting patients. As of November 4, 2011, 16 patients have been enrolled.

• The study objective is to identify the activity of toceranib phosphate alone or as a radiation sensitizing agent in the treatment of feline oral squamous cell carcinoma.  This is a partially funded, non-randomized study examining the efficacy of toceranib alone or in combination with palliative radiation therapy using 6 Gy X 6 biweekly fractions.

Examining the Efficacy of Toceranib Phosphate (Palladia®) as a Primary and/or Adjuvant Agent in the Treatment of Canine Nasal Carcinoma – Canine nasal carcinoma toceranib +/- RT.pdf (ACVR ID/Password required) This study is currently recruiting patients.  As of November 4, 2011, 24 patients have been enrolled.

• The study objective is to identify the activity of toceranib phosphate alone or as a radiation sensitizing agent in the treatment of canine nasal carcinoma. This is a partially funded, non-randomized study examining the efficacy of toceranib alone or in combination with radiotherapy using 4.2 Gy X 10 daily fractions.

Coarse fraction RT and/or ONCEPT™ Melanoma Vaccination for Canine Oral Melanoma – Canine oral melanoma study outline.pdf, Canine oral melanoma study data sheets.pdf This study is currently recruiting patients.

• The study objective is to evaluate the effect of coarse-fraction radiotherapy (8 Gy X 4 weekly fractions) in combination with the ONCEPT™ melanoma vaccine on the outcome of dogs with malignant oral melanoma.  Data for three treatment groups (concurrent RT and vaccine; RT alone; vaccine alone) will be collected.  Treatment selection will be based on owner’s preference. While this is designed as a prospective, non-randomized study, retrospective cases are welcome as long as inclusion criteria are met.

Guidelines and Quality Assurance Program Recommendations

• Download: vrtog_qa.pdf    

Grant Submission Format

• Download: vrtog_grants.pdf

VRTOG Radiation Morbidity Scoring Scheme

• Download: scoring_scheme.pdf

VRTOG Membership

* Contact Person